加拿大医护人员SARS-CoV-2 IgG应答及衰减的决定因素:一项前瞻性队列研究
加拿大跨省医护人员队列在首次免疫后4个月及7、10、13个月采血,用随机效应多因素模型分析抗RBD IgG滴度的影响因素。结果显示IgG随疫苗剂次和首次感染升高,随接种或感染后月数下降,第三剂后下降最陡;含mRNA-1273的免疫方案IgG更高;多发性硬化、类风湿关节炎及使用选择性免疫抑制剂等者IgG较低。
要点
- IgG滴度随疫苗剂次增加和首次感染而升高,随接种或感染后时间下降,第三剂后下降最陡。
- 含mRNA-1273(Moderna)的免疫方案抗RBD IgG更高。
- 多发性硬化、类风湿关节炎及使用选择性免疫抑制剂、TNF抑制剂、钙调神经磷酸酶抑制剂和抗肿瘤药者IgG较低。
核心结论
- 前瞻性队列的建立是本研究结果可信度的核心,系列血清学评估与纵向分析提供了更准确的效应估计,并更清晰地理解影响疫苗应答的医学及其他因素。
研究设计与样本
- 加拿大跨省医护人员队列研究,4567名已接种疫苗的队列参与者中2752人同意捐献至少一份血样。
- 在首次SARS-CoV-2免疫后4个月及7、10、13个月采集血样,共四次接触时收集免疫日期与类型、SARS-CoV-2感染日期及免疫损害状况和当前治疗信息。
- 血样集中检测抗RBD IgG和抗核衣壳IgG(Abbott Architect,Abbott Diagnostics),并用公共卫生机构的免疫和SARS-CoV-2检测记录评估报告错误对随机效应多因素模型估计的影响。
- 对8903份样本的抗RBD IgG滴度进行建模。
主要发现
- 抗RBD IgG滴度随每一剂疫苗和首次感染而升高。
- 抗RBD IgG滴度随接种或感染后月数增加而下降,第三剂后下降最陡。
- 含mRNA-1273(Moderna)的免疫方案抗RBD IgG更高。
- 报告多发性硬化、类风湿关节炎或使用选择性免疫抑制剂、肿瘤坏死因子抑制剂、钙调神经磷酸酶抑制剂和抗肿瘤药者抗RBD IgG较低。
- 补充分析显示报告疫苗副作用者抗RBD IgG更高,抗RBD IgG与肥胖无关,妊娠早期或中期免疫的女性滴度较低;敏感性分析结果提示自我报告数据无重要偏倚。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Healthcare workers (HCWs) from an interprovincial Canadian cohort gave serial blood samples to identify factors associated with anti-receptor binding domain (anti-RBD) IgG response to the SARS-CoV-2 virus. METHODS: Members of the HCW cohort donated blood samples four months after their first SARS-CoV-2 immunization and again at 7, 10 and 13 months. Date and type of immunizations and dates of SARS-CoV-2 infection were collected at each of four contacts, together with information on immunologically-compromising conditions and current therapies. Blood samples were analyzed centrally for anti-RBD IgG and anti-nucleocapsid IgG (Abbott Architect, Abbott Diagnostics). Records of immunization and SARS-CoV-2 testing from public health agencies were used to assess the impact of reporting errors on estimates from the random-effects multivariable model fitted to the data. RESULTS: 2752 of 4567 vaccinated cohort participants agreed to donate at least one blood sample. Modelling of anti-RBD IgG titer from 8903 samples showed an increase in IgG with each vaccine dose and with first infection. A decrease in IgG titer was found with the number of months since vaccination or infection, with the sharpest decline after the third dose. An immunization regime that included mRNA1273 (Moderna) resulted in higher anti-RBD IgG. Participants reporting multiple sclerosis, rheumatoid arthritis or taking selective immunosuppressants, tumor necrosis factor inhibitors, calcineurin inhibitors and antineoplastic agents had lower anti-RBD IgG. Supplementary analyses showed higher anti-RBD IgG in those reporting side-effects of vaccination, no relation of anti-RBD IgG to obesity and lower titers in women immunized in early or mid-pregnancy. Sensitivity analysis results suggested no important bias in the self-report data. CONCLUSION: Creation of a prospective cohort was central to the credibility of results presented here. Serial serology assessments, with longitudinal analysis, provided effect estimates with enhanced accuracy and a clearer understanding of medical and other factors affecting response to vaccination.
引用
- Cherry N, Adisesh A, Burstyn I, et al. Determinants of SARS-CoV-2 IgG response and decay in Canadian healthcare workers: A prospective cohort study. Vaccine. 2024. PMID: 38278628. doi:10.1016/j.vaccine.2024.01.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。